Related Experiment Video

Updated: Jun 11, 2026

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Kerry J Williams1, A Craig Lockhart

  • 1Department of Medicine, Division of Medical Oncology, Washington, University School of Medicine, St. Louis, MO, USA.

Oncotargets and Therapy
|July 10, 2010
PubMed

Insights

Targeted therapies like epidermal growth factor receptor (EGFR) inhibitors have improved colorectal cancer (CRC) outcomes. Panitumumab, an EGFR inhibitor, shows efficacy in metastatic CRC, especially in patients with wild-type KRAS.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Colorectal cancer (CRC) outcomes have improved with targeted therapies.
  • Epidermal growth factor receptor (EGFR) inhibitors are a successful strategy in CRC treatment.
  • EGFR is overexpressed in CRC, correlating with malignancy.

Purpose of the Study:

  • To evaluate the efficacy and safety of panitumumab, an EGFR inhibitor, in metastatic CRC.
  • To review the clinical utility of panitumumab in combination with other therapies.
  • To highlight the role of KRAS mutations in predicting response to EGFR inhibitors.

Main Methods:

  • Review of clinical trials and studies on EGFR inhibitors in metastatic CRC.
  • Analysis of panitumumab's efficacy, safety, and tolerability.
  • Investigation of KRAS mutation status as a predictive biomarker.

Main Results:

  • Panitumumab demonstrated an objective response rate of 10% versus 0% for best supportive care in a pivotal trial.
  • Panitumumab is a fully humanized monoclonal antibody with a reduced risk of hypersensitivity.
  • KRAS mutations predict efficacy, limiting panitumumab and cetuximab use to wild-type KRAS CRC patients.

Conclusions:

  • Panitumumab is an effective and well-tolerated treatment for metastatic CRC.
  • The identification of KRAS mutations has advanced personalized cancer care for CRC patients.
  • EGFR inhibitors represent a significant advancement in CRC targeted therapy.
Keywords:
KRAScetuximabcolorectal cancerepidermal growth factor receptorpanitumumab

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...